Standard SBRT for ultra-central lung tumors has been associated with an increased risk of severe toxicity particularly from the central airways. SUNSET was a phase 1 dose escalation study of definitive SBRT for ultracentral NSCLC. It included 30 patients whose PTV overlapped the central bronchial tree, esophagus, pulmonary artery, or pulmonary vein. Tumors with endobronchial invasion were not eligible. Most (77%) had T1 tumors with a median size of 2.6cm. The prescription dose was 60 Gy in 8 fractions with a max dose of 120% within the PTV. OAR constraints were prioritized over PTV coverage, and 27% required some degree of target undercoverage. The proximal bronchus and pulmonary vessels were limited to 64 Gy max and V60 <10cc. The primary endpoint of grade 3-5 toxicity was a favorable 6.7% (one grade 3 and one grade 5 event). At 3 years, local control was 89.6%, PFS was 66.1%, and OS was 72.5%. | Meredith, Int J Radiat Oncol Biol Phys 2024

